Education
About Us
Working with TipRanks
Follow Us
Heron Therapeutics (HRTX)
NASDAQ:HRTX
HRTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.04 - $2.68
Previous CloseN/A
Volume327.52K
Average Volume (3M)1.59M
Market Cap
$245.64M
Enterprise Value$454.93M
Total Cash (Recent Filing)$40.63M
Total Debt (Recent Filing)$176.74M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Nov 05, 2025EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding183,314,400
10 Day Avg. Volume1,801,707
30 Day Avg. Volume1,591,386
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.85
Enterprise Value/Revenue3.04
Enterprise Value/Gross Profit4.07
Enterprise Value/Ebitda65.69
Forecast
1Y Price Target
$4.50Price Target Upside240.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Commercial InitiativesMomentum is building ahead of expanded commercial initiatives and the launch of a dedicated Zynrelef sales team in the third quarter of 2025.
Product TransitionThe transition to the vial access needle (VAN) is expected to be completed in the third quarter, improving product preparation, handling, and field sterility in hospitals and ambulatory surgical centers nationwide.
Revenue GuidanceHeron reiterated its full-year revenue guidance of $153M to $163M, and the company has reported $76M in 1H25 revenue, making the guidance achievable.
Bears Say
Revenue UncertaintyThe expected revenue ramp on Zynrelef and Aponvie remains an uncertainty and an overhang.
Share PerformanceShares are down about 25%, likely due to trading technicals around the transactions and disappointment with the 2Q25 performance.
Top-line GrowthTop-line growth struggles continue due to disappointing sales in Zynrelef and Aponvie.
Heron Therapeutics News
HRTX FAQ
What was Heron Therapeutics’s price range in the past 12 months?
Heron Therapeutics lowest stock price was $1.04 and its highest was $2.68 in the past 12 months.
What is Heron Therapeutics’s market cap?
Heron Therapeutics’s market cap is $245.64M.
When is Heron Therapeutics’s upcoming earnings report date?
Heron Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 27 days.
How were Heron Therapeutics’s earnings last quarter?
Heron Therapeutics released its earnings results on Aug 08, 2025. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of -$0.01 by -$0.01.
Is Heron Therapeutics overvalued?
According to Wall Street analysts Heron Therapeutics’s price is currently Undervalued.
Does Heron Therapeutics pay dividends?
Heron Therapeutics does not currently pay dividends.
What is Heron Therapeutics’s EPS estimate?
Heron Therapeutics’s EPS estimate is -0.02.
How many shares outstanding does Heron Therapeutics have?
Heron Therapeutics has 183,314,400 shares outstanding.
What happened to Heron Therapeutics’s price movement after its last earnings report?
Heron Therapeutics reported an EPS of -$0.02 in its last earnings report, missing expectations of -$0.01. Following the earnings report the stock price went down -28.261%.
Which hedge fund is a major shareholder of Heron Therapeutics?
Currently, no hedge funds are holding shares in HRTX
Heron Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.50 (240.91% Upside)
$4.50 (240.91% Upside)
Blogger Sentiment
Bearish
HRTX Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $6.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-36.79%
12-Months-Change
Fundamentals
Return on Equity
40.36%
Trailing 12-Months
Asset Growth
6.40%
Trailing 12-Months
Company Description
Heron Therapeutics
Heron Therapeutics, Inc. (HRTX) is a biotechnology company focused on developing and commercializing innovative therapeutics for patients suffering from pain and cancer. The company operates primarily in the pharmaceutical sector, specializing in the development of products that address unmet medical needs, particularly in the areas of post-operative pain management and cancer treatment. Heron’s core products include its proprietary formulations designed to provide improved efficacy and safety profiles compared to existing treatments.
HRTX Company Deck
HRTX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Heron Therapeutics demonstrated strong financial performance with significant revenue and EBITDA growth, successful financing, and progress in product adoption, particularly for ZYNRELEF and APONVIE. However, transient revenue impacts and discrepancies in inventory and revenue growth were noted. Overall, the company's strategic initiatives and financial management indicate positive momentum.View all HRTX earnings summariesHRTX Stock 12 Month Forecast
Average Price Target
$4.50
▲(240.91% Upside)
Technical Analysis
Ocugen
―
Benitec Biopharma
―
Kodiak Sciences
―
Sagimet Biosciences, Inc. Class A
―
Neumora Therapeutics, Inc.
―
Ownership Overview
21.34% Insiders
7.66% Mutual Funds
39.10% Other Institutional Investors
24.05% Public Companies and
Individual Investors